Comparison of Pathological and Biochemical Outcomes after Radical Prostatectomy in Korean Patients with Serum PSA Ranges.
10.3346/jkms.2015.30.3.317
- Author:
Hye Won LEE
1
;
Hwang Gyun JEON
;
Byong Chang JEONG
;
Seong Il SEO
;
Seong Soo JEON
;
Han Yong CHOI
;
Hyun Moo LEE
Author Information
1. Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. besthml@medimail.co.kr
- Publication Type:Original Article ; Comparative Study
- Keywords:
Prostatic Neoplasms;
Prostate Biopsy;
Radical Prostatectomy;
Upgrading;
Upstaging
- MeSH:
Aged;
Disease-Free Survival;
Humans;
Male;
Middle Aged;
Neoplasm Recurrence, Local/*pathology;
Neoplasm Staging;
Prostate/*pathology/surgery;
Prostate-Specific Antigen/*blood;
*Prostatectomy;
Prostatic Neoplasms/*pathology/surgery;
Republic of Korea;
Retrospective Studies;
Treatment Outcome
- From:Journal of Korean Medical Science
2015;30(3):317-322
- CountryRepublic of Korea
- Language:English
-
Abstract:
The aim of this study was to assess surgical outcome at radical prostatectomy (RP) in Korean men with a serum prostate-specific antigen (PSA) level of 2.5 to 3.0 ng/mL and compared with those of patients who had a PSA level of 3.0-4.0 and 4.0-10.0 ng/mL. We retrospectively compared clinico-pathological characteristics and biochemical recurrence (BCR) risk in patients with PSA level of 2.5-3.0 (group 1, n = 92, 5.7%), 3.0-4.0 (group 2, n = 283, 17.5%), or 4.0-10.0 ng/mL (group 3, n = 1,242, 76.8%) who underwent RP between 1995 and 2013. The pathologic characteristics including Gleason score, pathologic stage, and percentage of significant cancer in group 1 were similar to those in group 2 and group 3. Furthermore, pathological upgrading and upstaging were found in 23 (30.7%) and 10 (14.7%) in group 1, 84 (33.9%) and 19 (8.8%) in group 2, and 321 (32.8%) and 113 (12.8%) in group 3, respectively, with no significant differences among the three groups (all P > 0.05). In multivariate analysis, PSA grouping was not an independent predictor of BCR. Within the population with PSA lower than 10 ng/mL, substratification of PSA is not a significant predictor for upgrading, upstaging, or adverse prognosis.
